Table 1.
Overview of the studies evaluated in this review
| Country (reference) | Number of individuals (n) | Subject type | Functional alleles | Reduced functional alleles | Nonfunctional alleles | Duplications | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1* | 2* | 10* | 17* | 41* | 3* | 4* | 5* | 6* | 2×× | |||
| Saudi Arabia[14] | 101 | Healthy | 79.1 | N/A | 3 | 3 | N/A | N/A | 3.5 | 1 | N/A | 10.4 |
| Saudi Arabia[13] | 192 | Healthy | 78.4 | N/A | N/A | N/A | 18.4 | 0 | N/A | N/A | 0 | N/A |
| Egypt[15] | 21+22 | Healthy + bladder cancer | 47.7 | N/A | N/A | N/A | N/A | 52.3* | N/A | N/A | ||
| Egypt[16] | 27+37 | Healthy + bladder cancer | 54.7 | N/A | N/A | N/A | N/A | 45.3* | N/A | N/A | ||
| Egypt[17] | 429+123 | Healthy + hypertensive cases | 85.1 | N/A | N/A | N/A | N/A | 14.9* | N/A | N/A | ||
| Egypt[18] | 11+32 | Healthy + acute leukemia | 53.5 | N/A | N/A | N/A | N/A | N/A | 46.5 | N/A | N/A | N/A |
| Egypt[20] | 308 | Healthy fertile and infertile | 74.4 | N/A | N/A | N/A | N/A | N/A | 25.6 | N/A | N/A | N/A |
| Egypt[21] | 29+30 | Healthy + chronic organophosphate exposed patients | 78 | N/A | N/A | N/A | N/A | N/A | 22 | N/A | N/A | N/A |
| Egypt[19] | 29+40 | Healthy + acute organophosphate exposed patients | 81.9 | N/A | N/A | N/A | N/A | N/A | 18.1 | N/A | N/A | N/A |
| Iran[25] | 100 | Healthy | 43.5 | 32 | 9 | 0 | N/A | N/A | 12.5 | 3 | N/A | N/A |
| Iran[26] | 100 | Healthy | 90 | N/A | N/A | N/A | N/A | 0.5 | 9 | N/A | 0.5 | N/A |
| Iran[27] | 101 | Breast cancer | 63.4 | N/A | N/A | N/A | N/A | N/A | 36.6 | N/A | N/A | N/A |
| Iran[24] | 300 | Healthy | 68.2 | N/A | 31.8 | N/A | N/A | N/A | 0 | N/A | N/A | N/A |
| Turkey[34] | 80+32 | Healthy + SLE patients | 85.3 | N/A | N/A | N/A | N/A | 0.4 | 14.3 | N/A | N/A | N/A |
| Turkey[41] | 53 | Ankylosing spondylitis patients | 84 | N/A | N/A | N/A | N/A | N/A | 16 | N/A | N/A | N/A |
| Turkey[45] | 100 | Healthy | 69 | N/A | 14.5 | N/A | N/A | 1 | 10 | 3 | 2.5 | N/A |
| Turkey[44] | 55+132 | Healthy + epileptic children patients | 81.8 | N/A | N/A | N/A | N/A | 0.8 | 17.4 | N/A | N/A | N/A |
| Turkey[43] | 30+60 | Responsive and nonresponsive FMF patients | 55 | N/A | N/A | N/A | N/A | 4.2 | 15.8 | 2.5 | 22.5 | N/A |
| Turkey[42] | 140+155+94 | Healthy + ALL + AML | 82.8 | N/A | N/A | N/A | N/A | 1.3 | 15.9 | N/A | N/A | N/A |
| Turkey[35] | 249 | Turkey with symptoms of arthritis, sacroiliac, joint and back pain | 87.8 | N/A | N/A | N/A | N/A | N/A | 12.2 | N/A | N/A | N/A |
| Turkey[32] | 160 | Healthy | 81 | N/A | N/A | N/A | 15 | N/A | N/A | N/A | N/A | N/A |
| Turkey[31] | 128+135 | Healthy + breast cancer patients | 66.3 | N/A | N/A | N/A | N/A | N/A | 33.7 | N/A | N/A | N/A |
| Turkey[38] | 52+100 | Healthy + ankylosing spondylitis patients | 83.9 | N/A | N/A | N/A | N/A | N/A | 16.1 | N/A | N/A | N/A |
| Turkey[33] | 140 | Healthy | 83.6 | N/A | N/A | N/A | N/A | 2.5 | 13.9 | N/A | N/A | N/A |
| Turkey[40] | 404 | Healthy | 37.06 | 35.3 | 6.06 | 1.11 | N/A | 0 | 11.3 | 1.49 | 0.74 | 1.98 |
| Turkey[37] | 100 | Healthy | 79 | N/A | N/A | N/A | N/A | N/A | 21 | N/A | N/A | N/A |
| Turkey[36] | 92 | Breast cancer patients | 42.4 | 19.6 | 6 | 0.6 | 15.2 | 1.6 | 10.3 | 1.1 | 1.6 | N/A |
| Turkey[39] | 200 | Healthy | 32 | 35 | 26 | N/A | N/A | 6 | 1 | N/A | N/A | N/A |
| Turkey[30] | 251 | Migraine patients | 81.9 | N/A | N/A | N/A | N/A | 0.4 | 17.7 | N/A | 0 | N/A |
| Emirates[23] | 50+101 | Healthy + antidepressants | 39.1 | 12.2 | 3.3 | 2.5 | 15.2 | N/A | 9 | N/A | N/A | 4.3 |
| Syria[29] | 51 | Healthy | 47.07 | 30.39 | 2.94 | 0 | N/A | 0 | 9.8 | 0.98 | 0.98 | 3.92 |
| Jordan[28] | 192 | Healthy | 50.6 | N/A | 14.8 | 8.3 | N/A | N/A | 12.8 | N/A | N/A | 13.5 |
*Related to the *3, *4, and *5 together. ALL=Acute lymphoid leukemia; AML=Acute myeloid leukemia; FMF=Familial Mediterranean fever; SLE=Systemic lupus erythematous; N/A=Not applicable